Squamous Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SQM006 MIFTS: 57	Squamous Cell Carcinoma Categories: Cancer diseases, Rare diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Squamous Cell Carcinoma

MalaCards integrated aliases for Squamous Cell Carcinoma:

Name: Squamous Cell Carcinoma ¹¹ ¹⁹ ⁷⁵ ²⁸ ⁵ ¹⁴ ¹⁶ ⁷¹

Carcinoma, Squamous Cell ¹⁹ ⁷⁵ ⁴³

Epidermoid Carcinoma ¹¹ ¹⁹ ⁷⁵

Squamous Cell Cancer ¹¹ ⁵³ ¹⁴

Squamous Cell Carcinoma - Category ⁷¹

Malignant Squamous Cell Neoplasm ⁷¹

Squamous Cell Carcinoma of Skin ⁷¹

Malignant Squamous Cell Tumor ¹¹

Squamous Cell Epithelioma ¹¹

Squamous Cell Skin Cancer ¹⁹

Neoplasms, Squamous Cell ⁴³

Carcinoma Squamous Cell ⁵³

Squamous Carcinoma ¹¹

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:1749

MeSH ⁴³ D002294 D018307

NCIt ⁴⁹ C2929

SNOMED-CT ⁶⁸ 154605007

EFO ¹⁶ EFO_0000707

UMLS ⁷¹ C0007137 C0553723 C0751688 more

Sources

Summaries for Squamous Cell Carcinoma

GARD: ¹⁹ Squamous cell carcinoma (SCC) is the second most common skin cancer. SCC most often affects individuals who are exposed to large amounts of sunlight. It is typically characterized by a red papule or plaque with a scaly or crusted surface; it may be suspected whenever a small, firm reddish-colored skin lesion, growth or bump appears on the skin, but it may also be a flat growth with a curly and crusted surface. Most often these growths are located on the face, ears, neck, hands and/or arms, but they may occur on the lips, mouth, tongue, genitalia or other area. The most common causes of SCC are radiation from the sun and arsenic exposure.

MalaCards based summary: Squamous Cell Carcinoma, also known as carcinoma, squamous cell, is related to squamous cell carcinoma, head and neck and esophageal cancer. An important gene associated with Squamous Cell Carcinoma is DDR2 (Discoidin Domain Receptor Tyrosine Kinase 2). The drugs Petrolatum and Mometasone furoate have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and tongue.

Disease Ontology: ¹¹ A carcinoma that derives from squamous epithelial cells.

Wikipedia: ⁷⁵ Squamous-cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

Sources

Related Diseases for Squamous Cell Carcinoma

Diseases related to Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2256)

#	Related Disease	Score	Top Affiliating Genes
1	squamous cell carcinoma, head and neck	33.8	SPRY4-IT1 MIR205 HOTAIR H19 EPIST
2	esophageal cancer	33.6	UCA1 MIR205 MALAT1 HOTAIR H19 CDKN2B-AS1
3	esophagus squamous cell carcinoma	33.6	TUG1 TINCR MALAT1 HOTAIR EPIST CASC9
4	oral squamous cell carcinoma	33.4	UCA1 TUG1 NEAT1 MIR205 MALAT1 HOTAIR
5	laryngeal squamous cell carcinoma	33.3	NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
6	nasopharyngeal carcinoma	32.7	NEAT1 MIR205 MALAT1 HOTAIR HNF1A-AS1 H19
7	lung squamous cell carcinoma	32.6	TUG1 DDR2 CCAT2
8	lung cancer susceptibility 3	32.2	TUG1 MIR205 MALAT1 HOTAIR HNF1A-AS1 H19
9	small cell cancer of the lung	32.0	TUG1 MALAT1 HOTAIR CCAT2
10	prostate cancer	31.9	UCA1 TUG1 SPRY4-IT1 NEAT1 MIR205 MALAT1
11	lung cancer	31.8	UCA1 TUSC7 TUG1 TINCR SPRY4-IT1 RIOX2
12	bladder cancer	31.8	ZEB1-AS1 UCA1 TUG1 TINCR SPRY4-IT1 MIR205
13	melanoma	31.8	UCA1 SPRY4-IT1 MIR205 MALAT1 HOTAIR H19
14	thyroid carcinoma	31.8	UCA1 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
15	cervical cancer	31.8	UCA1 TUG1 SPRY4-IT1 NEAT1 MIR205 MALAT1
16	thyroid cancer, nonmedullary, 1	31.7	NEAT1 MALAT1 HOTAIR H19
17	endometrial cancer	31.5	UCA1 TUSC7 TUG1 NEAT1 HOTAIR H19
18	gallbladder cancer	31.4	UCA1 TUG1 MALAT1 HOTAIR H19 CDKN2B-AS1
19	gastric adenocarcinoma	31.4	NEAT1 HOTAIR H19
20	gastric cardia adenocarcinoma	31.3	HOTAIR H19 EPIST
21	retinitis pigmentosa 11	31.2	UCA1 TUG1 NEAT1 HOTAIR CDKN2B-AS1 CCAT2
22	pancreatic cancer	31.1	UCA1 TUG1 SPRY4-IT1 NEAT1 MIR205 MALAT1
23	myeloma, multiple	31.1	UCA1 TUG1 MALAT1 HOTAIR H19
24	ovarian cancer	31.1	UCA1 TUG1 SPRY4-IT1 NEAT1 MIR205 MALAT1
25	bladder urothelial carcinoma	31.1	TUG1 MALAT1 HOTAIR
26	leukemia, acute myeloid	31.1	UCA1 TUSC7 TUG1 MALAT1 HOTAIR CDKN2B-AS1
27	cholangiocarcinoma	31.0	UCA1 TUG1 SPRY4-IT1 NEAT1 MALAT1 H19
28	renal cell carcinoma, nonpapillary	31.0	UCA1 TUG1 SPRY4-IT1 MALAT1 HOTAIR H19
29	gastrointestinal system cancer	30.9	MIR205 MALAT1 HOTAIR H19
30	pancreatic ductal adenocarcinoma	30.9	UCA1 TUSC7 MIR205 MALAT1 HOTAIR H19
31	congestive heart failure	30.6	TUSC7 HOTAIR CDKN2B-AS1
32	osteogenic sarcoma	30.6	ZEB1-AS1 UCA1 TUSC7 TUG1 NEAT1 MALAT1
33	ovarian epithelial cancer	30.6	MALAT1 HOTAIR H19 CCAT2
34	hepatocellular carcinoma	30.6	ZEB1-AS1 UCA1 TUSC7 TUG1 SPRY4-IT1 RIOX2
35	gastric cancer	30.6	ZEB1-AS1 UCA1 TUSC7 TUG1 TINCR SPRY4-IT1
36	pre-eclampsia	30.6	TUG1 SPRY4-IT1 MALAT1 HOTAIR H19
37	pituitary adenoma	30.3	MALAT1 HOTAIR H19 CCAT2
38	colorectal cancer	30.3	ZEB1-AS1 UCA1 TUSC7 TUG1 TINCR SPRY4-IT1
39	glioma	30.2	ZEB1-AS1 UCA1 SPRY4-IT1 NEAT1 MALAT1 HOTAIR
40	high grade glioma	30.1	TUSC7 TUG1 SPRY4-IT1 NEAT1 MALAT1 HOTAIR
41	retinitis pigmentosa	30.0	ZEB1-AS1 UCA1 TUG1 TINCR NEAT1 HOTAIR
42	osteoarthritis	29.8	HOTAIR H19 DDR2
43	skin squamous cell carcinoma	11.9
44	penis squamous cell carcinoma	11.8
45	cervical squamous cell carcinoma	11.8
46	tongue squamous cell carcinoma	11.8
47	palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal	11.8
48	conjunctival squamous cell carcinoma	11.8
49	vulva squamous cell carcinoma	11.8
50	basaloid squamous cell carcinoma	11.8

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma:

Sources

Symptoms & Phenotypes for Squamous Cell Carcinoma

Sources

Drugs & Therapeutics for Squamous Cell Carcinoma

Drugs for Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 545)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Petrolatum

Approved, Investigational

Phase 4

8009-03-8

Mometasone furoate

Approved, Investigational, Vet_approved

Phase 4

83919-23-7

4240 441336

Titanium dioxide

Approved

Phase 4

13463-67-7

Cevimeline

Approved

Phase 4

107233-08-9

83898 25137844 2684

Triamcinolone

Approved, Vet_approved

Phase 4

124-94-7

31307

Raltitrexed

Approved, Investigational

Phase 4

112887-68-0

104758 135400182

Diclofenac

Approved, Vet_approved

Phase 4

15307-86-5, 15307-79-6

3033

Tirbanibulin

Approved, Investigational

Phase 4

897016-82-9

23635314

Cetuximab

Approved

Phase 4

205923-56-4

Mitomycin

Approved

Phase 4

50-07-7

5746

Endostar protein

Phase 4

Endostatins

Phase 4

Anti-Allergic Agents

Phase 4

Cholinergic Agents

Phase 4

Muscarinic Agonists

Phase 4

Fibrin Tissue Adhesive

Phase 4

Tin Fluorides

Phase 4

Triamcinolone hexacetonide

Phase 4

Triamcinolone diacetate

Phase 4

Triamcinolone Acetonide

Phase 4

6436

Anti-Bacterial Agents

Phase 4

Antibiotics, Antitubercular

Phase 4

Alkylating Agents

Phase 4

Trioxsalen

Approved

Phase 3

3902-71-4

5585

Fluorouracil

Approved

Phase 3

51-21-8

3385

Hydroxyurea

Approved

Phase 2, Phase 3

127-07-1

3657

Crizotinib

Approved, Investigational

Phase 3

877399-52-5

11626560

Amifostine

Approved, Investigational

Phase 3

20537-88-6

2141

Megestrol acetate

Approved, Investigational, Vet_approved

Phase 3

595-33-5

11683

Cobalt

Approved, Experimental, Withdrawn

Phase 3

7440-48-4

104729

Doxycycline

Approved, Investigational, Vet_approved

Phase 3

564-25-0

54671203

Tocopherol

Approved, Investigational

Phase 3

1406-66-2

Dapsone

Approved, Investigational

Phase 3

80-08-0

2955

Minocycline

Approved, Investigational

Phase 3

10118-90-8, 13614-98-7

54675783 5281021

Levoleucovorin

Approved, Experimental, Investigational

Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Sodium citrate

Approved, Investigational

Phase 2, Phase 3

68-04-2

23431961

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

Calcipotriol

Approved

Phase 2, Phase 3

112965-21-6

5288783

Pembrolizumab

Approved

Phase 3

1374853-91-4

254741536

Cemiplimab

Approved, Investigational

Phase 3

1801342-60-8

Ipilimumab

Approved

Phase 3

477202-00-9

Pemetrexed

Approved, Investigational

Phase 3

150399-23-8, 137281-23-3

60843 446556 135565230

Olaparib

Approved

Phase 3

763113-22-0

23725625

Methotrexate

Approved

Phase 3

1959-05-2, 59-05-2

4112 126941

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

44424639 60780

Imiquimod

Approved, Investigational

Phase 3

99011-02-6

57469

Topotecan

Approved, Investigational

Phase 3

123948-87-8, 119413-54-6

60699 60700

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Erlotinib

Approved, Investigational

Phase 2, Phase 3

183319-69-9, 183321-74-6

176870

Docetaxel

Approved, Investigational

Phase 3

114977-28-5

148124

Interventional clinical trials:

(show top 50) (show all 2570)

#	Name	Status	NCT ID	Phase	Drugs
1	Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above	Unknown status	NCT03725423	Phase 4	Apatinib
2	An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation	Unknown status	NCT04132102	Phase 4	Afatinib
3	A Prospective Randomized Controlled Clinical Study of Albumin-bound Paclitaxel Combined With Cisplatin (AP Regimen) Versus Docetaxel Combined With Cisplatin (TP Regimen) Induced Chemotherapy in Advanced Head and Neck Squamous Tummor	Unknown status	NCT04766827	Phase 4	albumin-bound paclitaxel
4	Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy	Unknown status	NCT02495064	Phase 4	Mometasone Furoate Cream
5	A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Sodium Glycididazole in Concurrent Radiochemotherapy for the Treatment of Thoracic Esophageal Squamous Carcinoma	Unknown status	NCT00642239	Phase 4	placebo;Sodium Glycididazole
6	Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Based on Chemotherapy for Advanced Non-small Cell Lung Squamous Carcinoma Patients：a Randomized Controlled,Open, Multicenter Clinical Study	Unknown status	NCT02513342	Phase 4	Docetaxel;Cisplatin
7	A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip.	Completed	NCT00868088	Phase 4
8	Phase IV Clinical Study Evaluating The Efficacy of Chemoradiotherapy Following Neoadjuvant Treatment With Docetaxel and Cisplatin in Indifferentiated and Non-keratinized Squamous Cell Carcinoma of Nasopharynx	Completed	NCT00772681	Phase 4	docetaxel and cisplatin
9	Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study	Completed	NCT02088515	Phase 4	Nedaplatin;Cisplatin;Docetaxel
10	An Investigator-Initiated,Multicenter,Randomized,Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve OraL Health in Patients With XErostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma	Completed	NCT00466388	Phase 4	Cevimeline
11	Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma	Completed	NCT01453179	Phase 4	Imiquimod;Diclofenac
12	Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer	Completed	NCT03998696	Phase 4	Cisplatin 40 mg/m2;Cisplatin 100 mg/m2
13	Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors	Completed	NCT01344356	Phase 4
14	Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)	Completed	NCT02151149	Phase 4	nab-paclitaxel;Carboplatin
15	CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial	Completed	NCT00847912	Phase 4	5-fluorouracil;Placebo, vehicle control
16	Can Fibrin Sealant be Used to Reduce Post-operative Drainage Following Lymph Node Dissection: a Prospective Randomised Double Blind Trial.	Completed	NCT00324272	Phase 4	Fibrin Sealant (Tisseel) used in the Experimental Arm.
17	Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial	Recruiting	NCT03196843	Phase 4	Raltitrexed
18	A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients With Actinic Keratosis on the Face or Scalp	Recruiting	NCT05387525	Phase 4	Tirbanibulin (Klisyri®) 10 mg/g ointment;Diclofenac Sodium 3% Gel
19	Sun Yat-sen Memorial Hospital, Sun Yat-sen University	Recruiting	NCT05444673	Phase 4	Paprizumab combined with cisplatin and 5-FU
20	A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10).	Active, not recruiting	NCT04489888	Phase 4	Pembrolizumab;Carboplatin;Paclitaxel
21	Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck	Terminated	NCT02015650	Phase 4	Cetuximab;Mitomycin-C/ 5-Fluorouracil
22	Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx	Withdrawn	NCT03388931	Phase 4
23	Acitretin Plasma Levels Under Hemodialysis	Withdrawn	NCT00488384	Phase 4	Chemopreventive application (Acitretin)
24	Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer	Unknown status	NCT02628665	Phase 3	photosensitizer(photofrin)
25	Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer	Unknown status	NCT02025036	Phase 3	Capecitabine(Aibin);Oxaliplatin(Aiheng)
26	Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer	Unknown status	NCT02607540	Phase 3
27	Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy	Unknown status	NCT02603159	Phase 3	Capecitabine(Aibin)
28	Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma	Unknown status	NCT01947062	Phase 3	Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
29	SCT-I10A Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase III, Multicenter, Randomized, Double-blinded Trial	Unknown status	NCT04146402	Phase 3	SCT-I10A+chemo;Placebos+chemo
30	A Multicenter, Randomized, Open-label, Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Patients Undergoing Radical Esophagectomy for Pathologic Lymph Node Positive Esophageal Squamous Cell Carcinoma	Unknown status	NCT02570893	Phase 3	Paclitaxel and carboplatin
31	Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma	Unknown status	NCT01874171	Phase 3	Cisplatin;Cetuximab
32	Multicenter, Randomized, Double-blind, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of TQB2450 Plus Chemotherapy（Cisplatin or Carboplatin+ 5-Fluorouracil (5-FU) ） Versus Placebo Plus Chemotherapy as First-Line Treatment in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma（R/M SCCHN）	Unknown status	NCT03855384	Phase 3	TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU);placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
33	An Open, Multicenter, Randomized Phase III Clinical Study on Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma	Unknown status	NCT02677597	Phase 3	Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel
34	A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region	Unknown status	NCT02630264	Phase 3	Endostatins;Paclitaxel injection;Cisplatin injection
35	RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY AND SURGERY +/- RADIOTHERAPY VERSUS SURGEERY +/- RADIOTHERAPY IN OPERABLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY	Unknown status	NCT00002747	Phase 3	cisplatin;fluorouracil
36	Randomised Clinical Phase III Study of Radiotherapy Dose, Volume Evaluation for 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Squamous Cell Carcinoma	Unknown status	NCT01124409	Phase 3
37	Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma (ESWN 01 Trial): a Phase 3, Prospective,Multicenter, Randomised Study	Unknown status	NCT02319187	Phase 3	S1;S-1;irinotecan
38	Observational Clinical Trial of Adjuvant Chemotherapy for Non-squamous Cell Carcinoma of Non-small Cell Lung Cancer	Unknown status	NCT03656393	Phase 3	Gefitinib;Vinorelbine;Carboplatin
39	Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study	Unknown status	NCT00336947	Phase 3	tegafur-gimeracil-oteracil potassium;tegafur-uracil
40	A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF CISPLATIN/EPINEPHRINE INJECTABLE GEL (PRODUCT MPI 5010) WHEN ADMINISTERED INTRATUMORALLY FOR ACHIEVEMENT OF TREATMENT GOALS IN RECURRENT OR REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK	Unknown status	NCT00002659	Phase 3	cisplatin-e therapeutic implant
41	A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma	Unknown status	NCT02409186	Phase 3	Nimotuzumab;chemoradiotherapy Paclitaxel;chemoradiotherapy Cisplatin
42	Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx	Unknown status	NCT00002702	Phase 3
43	The Randomized,Open, Multicenter Phase III Study to Compare the Effectiveness and Safety of Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin First-Line Therapy Advanced Non Small Cell Lung Cancer Squamous Cell Carcinoma	Unknown status	NCT03262948	Phase 3	nab-paclitaxel;Paclitaxel;Carboplatin
44	A Randomized Phase II Trial Evaluating The Addition Of Nimotuzumab To Chemoradiation For Patients With Esophageal Squamous Cell Carcinoma After Radical Esophagectomy Who Suffer With Lymph Nodes Recurrence	Unknown status	NCT01402180	Phase 2, Phase 3	chemotherapy
45	Multi-center Prospective Randomized Controlled Clinical Trial of Postoperative Adjuvant Chemotherapy, Adjuvant Radiotherapy, or Surgery Alone for High-risk Histological Node Negative Patients With Thoracic Esophageal Squamous Cell Carcinoma	Unknown status	NCT02891083	Phase 3	Adjuvant chemotherapy (Paclitaxel and Cisplatin)
46	Phase Ⅲ Study of Prophylactic Postoperative Intensity Modulated Radiation Therapy in Stage T2-3N0M0 Disease of Thoracic Esophageal Squamous Cell Carcinoma;	Unknown status	NCT01745107	Phase 3
47	Is Elective Nodal Irradiation (ENI) Necessary For Patients With Thoracic Esophageal Squamous Cell Carcinoma Who Undergo Esophagectomy And With Pathological Stage Of T1-2,N+,M0 -- A Randomized Phase Ⅲ Trial	Unknown status	NCT01398449	Phase 3
48	Chemoprevention of Esophageal Squamous Cell Carcinoma With Aspirin and Tea Polyphenols: a Randomized Controlled Trial.	Unknown status	NCT01496521	Phase 3	Aspirin
49	Postoperative Radiation and Concurrent Chemotherapy With Weekly Docetaxel Versus Cisplatin in Patients With High Risk Squamous Cell Carcinoma of Head & Neck: a Randomized Multi-center Phase III Clinical Trial	Unknown status	NCT02923258	Phase 2, Phase 3	Docetaxel;Cisplatinum
50	International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)	Unknown status	NCT02305654	Phase 3	Paclitaxel;Ifosfamide;Cisplatin

Search NIH Clinical Center for Squamous Cell Carcinoma

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Afatinib

afatinib dimaleate

pembrolizumab

Cochrane evidence based reviews: carcinoma, squamous cell

Sources

Genetic Tests for Squamous Cell Carcinoma

Genetic tests related to Squamous Cell Carcinoma:

#	Genetic test	Affiliating Genes
1	Squamous Cell Carcinoma ²⁸

Sources

Anatomical Context for Squamous Cell Carcinoma

Organs/tissues related to Squamous Cell Carcinoma:

MalaCards : Skin, Lymph Node, Tongue, Lung, Cervix, T Cells, Myeloid

Sources

Publications for Squamous Cell Carcinoma

Articles related to Squamous Cell Carcinoma:

(show top 50) (show all 47763)

#	Title	Authors	PMID	Year
1	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. ⁵	MacConaill LE...Lindeman NI	25157968	2014
2	Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. ⁵	Pitini V...Altavilla G	23932362	2013
3	Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. ⁵	Hammerman PS...Meyerson M	22328973	2011
4	Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. ⁵	Day E...Jarai G	18938156	2008
5	Expression of CC-chemokine receptor 7 (CCR7) and CXC-chemokine receptor 4 (CXCR4) in head and neck squamous cell carcinoma. ⁵³ ⁶²	Ueda M...Kannagi R	20036791	2010
6	Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2. ⁵³ ⁶²	Ohtsu N...Urade M	20514441	2010
7	Carrier cell-mediated cell lysis of squamous cell carcinoma cells by squamous cell carcinoma antigen 1 promoter-driven oncolytic adenovirus. ⁵³ ⁶²	Hamada K...Hamakawa H	20527047	2010
8	Tumor-related protein, the squamous cell carcinoma antigen binds to the intracellular protein carbonyl reductase. ⁵³ ⁶²	Murakami A...Sugino N	20428762	2010
9	EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. ⁵³ ⁶²	Sundvall M...Elenius K	20415599	2010
10	Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer. ⁵³ ⁶²	Saarilahti K...Makitie AA	20470671	2010
11	Expression and mutation analysis of her2 in head and neck squamous cell carcinoma. ⁵³ ⁶²	Ali MA...Nagatsuka H	20014947	2010
12	Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck. ⁵³ ⁶²	Liu FY...Sun CF	19615795	2010
13	EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. ⁵³ ⁶²	Faoro L...Salgia R	20360610	2010
14	Downregulation of N-cadherin expression inhibits invasiveness, arrests cell cycle and induces cell apoptosis in esophageal squamous cell carcinoma. ⁵³ ⁶²	Li K...Fan QX	20014942	2010
15	Nerve growth factor and tyrosine kinase A receptor in oral squamous cell carcinoma: is there an association with perineural invasion? ⁵³ ⁶²	Kolokythas A...Schmidt BL	20363547	2010
16	Loss expression of O6-methylguanine DNA methyltransferase by promoter hypermethylation and its relationship to betel quid chewing in oral squamous cell carcinoma. ⁵³ ⁶²	Huang SH...Hsia KT	20451846	2010
17	Naphtho[1,2-b]furan-4,5-dione induces apoptosis of oral squamous cell carcinoma: involvement of EGF receptor/PI3K/Akt signaling pathway. ⁵³ ⁶²	Chien CM...Lin SR	20371243	2010
18	Reactive oxygen species produced by the knockdown of manganese-superoxide dismutase up-regulate hypoxia-inducible factor-1alpha expression in oral squamous cell carcinoma cells. ⁵³ ⁶²	Sasabe E...Yamamoto T	20188165	2010
19	Potential role of HDAC inhibitors in cancer therapy: insights into oral squamous cell carcinoma. ⁵³ ⁶²	Iglesias-Linares A...Gonzalez-Moles MA	20207580	2010
20	Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. ⁵³ ⁶²	Kreppel M...Zoller JE	20393745	2010
21	Decreased GRP78 protein expression is a potential prognostic marker of oral squamous cell carcinoma in Taiwan. ⁵³ ⁶²	Huang TT...Chen HR	20497865	2010
22	The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells. ⁵³ ⁶²	Matsushita S...Akiyama S	20372793	2010
23	Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo. ⁵³ ⁶²	Koberle B...Albers AE	20372803	2010
24	TGFbeta1 genetic polymorphism is associated with survival in head and neck squamous cell carcinoma independent of the severity of chemoradiotherapy induced mucositis. ⁵³ ⁶²	Lundberg M...Mattila PS	20308003	2010
25	Regulation of p63 isoforms by snail and slug transcription factors in human squamous cell carcinoma. ⁵³ ⁶²	Herfs M...Delvenne P	20150431	2010
26	E-cadherin differentially regulates the assembly of Connexin43 and Connexin32 into gap junctions in human squamous carcinoma cells. ⁵³ ⁶²	Chakraborty S...Mehta PP	20086013	2010
27	Inhibitory effect of curcumin on motility of human oral squamous carcinoma YD-10B cells via suppression of ERK and NF-kappaB activations. ⁵³ ⁶²	Shin HK...Kim SH	19777504	2010
28	Aspirin induces apoptosis in YD-8 human oral squamous carcinoma cells through activation of caspases, down-regulation of Mcl-1, and inactivation of ERK-1/2 and AKT. ⁵³ ⁶²	Park IS...Jang BC	20116423	2010
29	Plakoglobin interacts with and increases the protein levels of metastasis suppressor Nm23-H2 and regulates the expression of Nm23-H1. ⁵³ ⁶²	Aktary Z...Pasdar M	20101217	2010
30	Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation. ⁵³ ⁶²	Wang H...Rapraeger AC	20181947	2010
31	HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. ⁵³ ⁶²	Bandoh N...Harabuchi Y	20204276	2010
32	Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. ⁵³ ⁶²	Niu G...Chen X	20215534	2010
33	Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. ⁵³ ⁶²	Kondo N...Matsuda H	20204279	2010
34	TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. ⁵³ ⁶²	Kupferman ME...Myers JN	20101235	2010
35	[Expression of alpha-tubulin and MDR1 and their correlation with the biological features of non-small cell lung carcinoma]. ⁵³ ⁶²	Chen QY...Zhou JY	20510079	2010
36	Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues. ⁵³ ⁶²	Zhang G...Wu W	19823871	2010
37	[Clinicopathological significance of expressions of RECK and MMP-2 in esophageal squamous carcinoma]. ⁵³ ⁶²	Qi M...Li Y	20510080	2010
38	The predictive value of genes of the TGF-beta1 pathway in multimodally treated squamous cell carcinoma of the esophagus. ⁵³ ⁶²	Puhringer-Oppermann F...Brucher BL	20012971	2010
39	Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma. ⁵³ ⁶²	Takeshita H...Otsuji E	20389301	2010
40	mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. ⁵³ ⁶²	Hou G...Xue L	19853373	2010
41	Vimentin expression of esophageal squamous cell carcinoma and its aggressive potential for lymph node metastasis. ⁵³ ⁶²	Jin H...Kijima H	20460738	2010
42	p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma. ⁵³ ⁶²	Taghavi N...Abbaszadegan MR	20388212	2010
43	VEGF-C contributes to head and neck squamous cell carcinoma growth and motility. ⁵³ ⁶²	Benke EM...Yeudall WA	20227330	2010
44	GLUT1 and GLUT3 as potential prognostic markers for Oral Squamous Cell Carcinoma. ⁵³ ⁶²	Ayala FR...Soares FA	20428049	2010
45	Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. ⁵³ ⁶²	Fang LY...Chen YL	20040021	2010
46	Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. ⁵³ ⁶²	Eckert AW...Bilkenroth U	19780905	2010
47	Two members of the SIBLING family of proteins, DSPP and BSP, may predict the transition of oral epithelial dysplasia to oral squamous cell carcinoma. ⁵³ ⁶²	Ogbureke KU...Fisher LW	20186700	2010
48	Minichromosome maintenance-7 and geminin are reliable prognostic markers in patients with oral squamous cell carcinoma: immunohistochemical study. ⁵³ ⁶²	Tamura T...Ito H	20136698	2010
49	Clinical significance of EGFR, Her-2 and EGF in oral squamous cell carcinoma: a case control study. ⁵³ ⁶²	Bernardes VF...Aguiar MC	20429940	2010
50	Cobalt chloride stimulates phosphoinositide 3-kinase/Akt signaling through the epidermal growth factor receptor in oral squamous cell carcinoma. ⁵³ ⁶²	Ryu MH...Park HR	20506627	2010

Sources

Genes for Squamous Cell Carcinoma

Genes related to Squamous Cell Carcinoma (2 elite genes):

(show top 50) (show all 151)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	DDR2	Discoidin Domain Receptor Tyrosine Kinase 2	Protein Coding	406.53	Pathogenic ⁵ DISEASES inferred ¹⁴	22328973 18938156 23932362
2	MIR205	MicroRNA 205	RNA Gene	369.72	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	19033458
3	CASC9	Cancer Susceptibility 9	RNA Gene	174.31	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name (show sections)	24222893
4	PICSAR	P38 Inhibited Cutaneous Squamous Cell Carcinoma Associated LincRNA	RNA Gene	172.99	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name (show sections)	27049681
5	RIOX2	Ribosomal Oxygenase 2	Protein Coding	170.72	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications Expressions (show sections)	24757675
6	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	166	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	23717443 24022190 24118380 (more) 24151120 24222893 24757675 24788237 24817925
7	UCA1	Urothelial Cancer Associated 1	RNA Gene	164.97	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	17416635 25550835 27267823
8	TUG1	Taurine Up-Regulated 1	Protein Coding	164.85	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	25366138 27329359
9	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	RNA Gene	164.55	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	26609486
10	CDKN2B-AS1	CDKN2B Antisense RNA 1	RNA Gene	164.34	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	24747824
11	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	164.09	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	22996375 24706416 10597307
12	SPRY4-IT1	SPRY4 Intronic Transcript 1	RNA Gene	164.04	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	24810925 25608466 26883252 (more) 27250657
13	CCAT2	Colon Cancer Associated Transcript 2	RNA Gene	163.78	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	25677908 25919911 26722527
14	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	163.76	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	25538231 25613496 26406400 (more) 26493997
15	TINCR	TINCR Ubiquitin Domain Containing	Protein Coding	163.75	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	24115003 27819679
16	HNF1A-AS1	HNF1A Antisense RNA 1	RNA Gene	163.24	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	25608466
17	ZEB1-AS1	ZEB1 Antisense RNA 1	RNA Gene	163.15	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	26617942
18	EPIST	Esophagus Epithelial Intergenic Associated Transcript	RNA Gene	162.96	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	26158411
19	FOXCUT	FOXC1 Upstream Transcript	RNA Gene	162.92	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	25031703
20	TUSC7	Tumor Suppressor Candidate 7	RNA Gene	162.67	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	25169763
21	SOX2-OT	SOX2 Overlapping Transcript	RNA Gene	155.99	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	24105929 24817925 26862518
22	PCAT1	Prostate Cancer Associated Transcript 1	RNA Gene	155.64	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25731728
23	LINC01503	Long Intergenic Non-Protein Coding RNA 1503	RNA Gene	155.16	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29454790
24	LINC01234	Long Intergenic Non-Protein Coding RNA 1234	RNA Gene	154.96	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	24522499
25	BCYRN1	Brain Cytoplasmic RNA 1	RNA Gene	154.95	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27143917
26	CBR3-AS1	CBR3 Antisense RNA 1	RNA Gene	154.91	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	24337686
27	POU6F2-AS2	POU6F2 Antisense RNA 2	RNA Gene	154.9	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27033944
28	BOK-AS1	BOK Antisense RNA 1	RNA Gene	154.29	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25749038
29	LINC00951	Long Intergenic Non-Protein Coding RNA 951	RNA Gene	154.2	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	23872665
30	PANTR1	POU3F3 Adjacent Non-Coding Transcript 1	RNA Gene	153.13	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	24631494 25608466
31	LINC01426	Long Intergenic Non-Protein Coding RNA 1426	RNA Gene	153	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25486427
32	LINC01233	Long Intergenic Non-Protein Coding RNA 1233	RNA Gene	150	Experimental evidence: Expression ³⁷	24522499
33	EGFR	Epidermal Growth Factor Receptor	Protein Coding	82.74	Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	25157968 18832597 19670535 (more) 15986037 17020453 17168674 20130423 20470671 10807365 11895903 12700278 19276369 19886531 18380996 18045070 10328593 17234784 20130810 17307140 14763146 15700625 16115926 18236715 20215534 15598588 17283074 17310847 9828815 16550055 9816015 7970803 18507008 16854613 18620726 7659795 19543508 16648870 15338866 8442944 20028750 1904421 15205458 16750322 7700225 2015605 18032952 9625170 1702347 15871288 12147092 11307060 15694044 1910383 1485594 9864429 8291440 9822654 11848502 17342332 9930679 8080726 1389683 1692767 20036807 19454359 18980991 18768215 17342092 7882337 8205534 7915963 18347929 18473353 16818711 17622245 17487368 8039107 19772171 18097577 16988582 16565089 16540898 16059652 15920558 12573759 17496429 17178880 15736426 15610907 15466396 10873065 11706420 1624295 19823871 19398252 19360742 18808311 18045646 16875628 17224267 16161046 14977838 11275796 10693240 9816249 2024456 20077907 18754871 18528899 17785763 17674766 16799709 16763280 16103736 9495132 2389590 20506627 20415599 20193370 9294612 15878755 11746830 11459199 11078908 9664130 9427803
34	TP53	Tumor Protein P53	Protein Coding	61.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions Functions (show sections)	9127380 8826924 10445528 (more) 11255264 11244963 9778107 9133458 11314535 8692535 10518106 20062014 7675772 11812371 11835811 9058139 11552722 14976535 7762998 7703803 14724903 11679937 9683820 9683807 8456936 18455580 16778101 17060721 17949661 12816712 9035506 8691320 8094033 7781789 9027617 8879297 11480000 10862014 20142252 10491016 1486218 7665695 15899218 10828711 10677910 9720535 9703805 8895679 12189502 12001023 11836677 10487550 9450841 9066606 7533995 16998595 12408557 17557566 16086069 16075975 16127293 10389975 10215440 9001343 8606380 7922972 11914604 11206631 10091798 10605694 9692054 9816078 7917913 8398064 8168036 17380529 11562772 11478700 11480024 8714263 7747282 7882337 15831046 11297255 16237768 11244999 9049184 19751907 14582705 10414702 9190999 9158397 1519662 1463117 7682763 9592286 9930364 9719502 9703282 9578641
35	CCND1	Cyclin D1	Protein Coding	54.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)	10474686 1568216 8426754 (more) 15509364 15709184 15814622 8136159 11019942 10766394 17067457 9816282 11870667 14571727 16353790 11315260 11978554 10537346 9815619 12185899 20396569 10745172 7867006 9497916 15894358 9683778 17197212 9824094 11696452 9813719 11410884 11504311 11098077 14981992 18942709 17498553 16053486 12167432 11743641 10492044 9988238 9158396 17309796 11470749 18704459 17695500 12798405 8902564 15846092 15776189 9192552 7927946 17893905 15684005 10955801 10639568 10390005 10376532 20389301 8004570 7812927 20103831 17060721 16644573 16844559 15672286 10235369 9796972 9840520 10697609 12792768 15354413 15723720 17563903 15695117 12412169 11566495 11391257 10344760 10604413 10574260 9214595 15592503 15603389 15063391 12579289 9042789 9816104 7866635 8474448 15896460 19787783 19448414 19216775 18413827 17549378 17045795 16273238 15307143 12514403 11920603 10834541 9421073 17909038 16235239 11115554 17357088 17080019
36	PTEN	Phosphatase And Tensin Homolog	Protein Coding	52.5	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions Functions (show sections)	17067457 16482604 11735811 (more) 9688299 12370746 15684005 17958724 20079266 11932897 18497947 18260377 10215192 16084946 15129904 15517593 11401316 16849541 15196854 10889927 15025970 12224530 19125794 17475427
37	SERPINB3	Serpin Family B Member 3	Protein Coding	52.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Gene name Functions (show sections)	11241309 11182054 10653592 (more) 7687515 12743426 17549365 11369142 14993646 7589435 18657489 7724531 9602079 9008232 11172595 14654899 15733534 9329607 14630915 17016656 16820922 16211231 10867615 8638540 2020345 18385761 17506483 15986332 17523076 17238969 16865273 16824735 16549498 15887222 15286970 14647462 9817977 20428762 20089382 19166818 18344408 18097581 16641548 16398401 15203215 11389143 11267667 10873412 8999871 20509274 18673143 17582392 7681461 20527047 17291250 9931463 8694535 19332150 17893121 15825162 15350549 15203214 15192315 14648927 11722574 19956912 19112206 18959756 12888894 10845558 17364691 14970861 16550605 16820864 18638391
38	SERPINB4	Serpin Family B Member 4	Protein Coding	52.27	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Gene name Functions (show sections)	11241309 16710347 20527047 (more) 11267667 16006770 15192315 11182054 10956412 10653592 11172595 19125792 14630915 9811823 12940509 18497852 10512713 8674591 18673143 14647462 12949073 16035113 11722574 10867615 16238792 12421571 19339807 12702576
39	NOTCH1	Notch Receptor 1	Protein Coding	50.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries Pathways & Interactions (show sections)	19550121 20337085 20077907 (more) 19398252 17927876 19923082 20193370 17353266 20127005 16608439
40	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	49.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries Pathways & Interactions (show sections)	15160999 1996309 9119742 (more) 19229701 19380522 8389672
41	TGFBR2	Transforming Growth Factor Beta Receptor 2	Protein Coding	49.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions Functions (show sections)	11253131 10995883 8878454 (more) 9395234 10448730 11195465 7664267 17680270 11410498 12920253 9581843 10389906 17676583 16702406 16478646
42	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	48.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	12429789 15328914 8705996 (more) 9440786 9333024 13679459 7658499 19212685 17721272 12206014 14680586 12861061 9525287 11101148 10047686 12861066 10605694 9514803 20004950 15257310 11825926 14983256 11337265 8752149 16998595 16931955 16999361 17060721 19101490 10537346 9815619 9125147 11555154 15373786 18199718 8986966 14719099 9751261 14518304 19465901 17539962 16646054 12875969 11960918 10235368 16227635 15849750 14991744 11355167 9683778 17893905 15930346 12932666 10030668 20103831 17415114 12539460 18315600 18269647 20090213 20032395 16467168 15870532 15213596 15191661 14732922 14732771 16844559 9241072 8797577 9816078 15197677 10694947 19954817 17970080 17541467 12672028 12475418 11595706 10376532 10537333 14613656 12507294 18753959 17563903 15260845 12208744 10492034 8920671 10498902 12761983 15140233 15025970 14571727 14501820 11804749 11309302 11255261 11012984
43	TP63	Tumor Protein P63	Protein Coding	45.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Gene name Pathways & Interactions (show sections)	19744186 16680154 15254760 (more) 11764070 15551738 16021499 16681688 17637751 14997391 19160863 15309021 12447998 11336476 19716157 15754296 12210069 16415794 12782800 15564824 19517019 19391123 17391296 17255774 15458526 12946229 17882659 17499344 14612504 16391849 20150431 16687923 16647951 17018588 16885742 12378518 15369222 17418619 20081800 11727253 12884041 15363316 15863843 20195168 18787630 19700941 17936670 17909026 17477357 15268709 12760288 11536043 15608417 11531258 19725154 18091384 18085379 16413463 19577853 18194839 17822623 17149967 16861923 15608418 15307143 15201986 15189821 11948487 20181105 17276940 16724007 16101176 10594758 15033906 20442293 18087216 18284937 18064689 16776716 16328355 16082248 15583543 14989490 11839669 11172034 18783348 19476522 16273222
44	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	44.96	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	7736397 9800975 16866851 (more) 1377893 17342332 2269935 7576473 15785739 19362044 14748745 16264381 17357088 19786214 1683776 15172638 11458821 11275796 9815530 1348920 17825601 18251938 17674766 18364263 15284539 11342901 18032952 15809707 10632356 8097369 18704459 9217824 17622245 16029927 1672262 7552863 10750777 15014805 9885382 10754210 18818943 18172732 17315173 15902485 15642276 15476268 15103197 11839675 11480225 14558950 15865067 12867060 11879619 11751524 10928158 8687165 8102801 16965995 12866417 11823980 8389672 19128465 17069674 17238969 15672286 15692721 12384807 9387420 8831062 20064507 15256466 14639106 12861629 12688680 11673832 20204279 18754871 16033092 19691460 18849186 17969407 15236790 10810387 10738256 1363518 20014947 20237991 19827890 16818711 16000588 15599594 15307143 15068324 14991535 12960141 11894014 11120483 10380748 10048471 20429940
45	RB1	RB Transcriptional Corepressor 1	Protein Coding	42.44	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	12206014 12861066 9514803 (more) 10605694 9713590 10353761 10226595 10621854 8302602 8200275 7932807 11498850 8174043 15083191 20226061 19661312 15668901 10029452 9017583 17521451 16920543 11267938 16866858 12478659 12518864 11508622 10440744 9483214 9108451 10458687 17487398 19465901 11287287 19424974 10492034 10819064
46	CTTN	Cortactin	Protein Coding	42.16	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Gene name Functions (show sections)	10955801 19125793 17909038 (more) 18607838 16527272 19207554 18931703 17178864 9054437 17483334 9681820 11439336 8552396 11064458 16912177 8474448 7685625 16235239 15833860 18268492
47	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	41.89	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	16533766 18262558 17052259 (more) 17549376 12375266 18283320 19212681 18097548 20371243 16930767 17848307 18757405 12796399 19615795 17202311 15317667 20416519 17992665
48	CASP8	Caspase 8	Protein Coding	40.18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	19778795 18501034 17425843 (more) 19852930 10676636 20086182 16722146 19846952 15289875
49	SMAD4	SMAD Family Member 4	Protein Coding	38.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	9197523 16478646 10995883 (more) 12209716 14712482 10810347 20012971 17023741 15736400 15867212 19841536 16849541
50	EGFR-AS1	EGFR Antisense RNA 1	RNA Gene	38.31	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	25157968

Sources

Variations for Squamous Cell Carcinoma

ClinVar genetic disease variations for Squamous Cell Carcinoma:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	DDR2	NM_006182.4(DDR2):c.2304T>A (p.Ser768Arg)	SNV	Pathogenic	375878	rs267598140	GRCh37: 1:162748390-162748390 GRCh38: 1:162778600-162778600
2	EGFR-AS1, EGFR	NM_005228.5(EGFR):c.2428G>A (p.Gly810Ser)	SNV	Likely Pathogenic	376278	rs121913230	GRCh37: 7:55249130-55249130 GRCh38: 7:55181437-55181437
3	EGFR-AS1, EGFR	NM_005228.5(EGFR):c.2429G>A (p.Gly810Asp)	SNV	Likely Pathogenic	376279	rs121913431	GRCh37: 7:55249131-55249131 GRCh38: 7:55181438-55181438

Cosmic variations for Squamous Cell Carcinoma:

⁸ (show top 50) (show all 1992)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM112254631	TP53	skin,face,carcinoma,squamous cell carcinoma	c.586C>T	p.R196*	17:7674945-7674945	18
2	COSM143943797	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.266G>A	p.R89Q	17:7674220-7674220	18
3	COSM121875437	TP53	skin,face,carcinoma,squamous cell carcinoma	c.178C>T	p.Q60*	17:7674957-7674957	18
4	COSM143388508	TP53	skin,face,carcinoma,squamous cell carcinoma	c.629G>C	p.R210T	17:7674217-7674217	18
5	COSM111758868	TP53	skin,face,carcinoma,squamous cell carcinoma	c.742C>T	p.R248W	17:7674221-7674221	18
6	COSM142560384	TP53	skin,face,carcinoma,squamous cell carcinoma	c.616G>T	p.G206C	17:7674230-7674230	18
7	COSM144021997	TP53	skin,face,carcinoma,squamous cell carcinoma	c.421C>T	p.P141S	17:7675158-7675158	18
8	COSM144658487	TP53	skin,face,carcinoma,squamous cell carcinoma	c.143C>A	p.P48Q	17:7676109-7676109	18
9	COSM142639459	TP53	skin,face,carcinoma,squamous cell carcinoma	c.597T>A	p.C199*	17:7674249-7674249	18
10	COSM105620390	TP53	skin,face,carcinoma,squamous cell carcinoma	c.733G>T	p.G245C	17:7674230-7674230	18
11	COSM112263720	TP53	skin,face,carcinoma,squamous cell carcinoma	c.832C>T	p.P278S	17:7673788-7673788	18
12	COSM93239210	TP53	skin,face,carcinoma,squamous cell carcinoma	c.706T>C	p.Y236H	17:7674257-7674257	18
13	COSM105620642	TP53	skin,face,carcinoma,squamous cell carcinoma	c.742C>T	p.R248W	17:7674221-7674221	18
14	COSM143949062	TP53	skin,face,carcinoma,squamous cell carcinoma	c.263A>C	p.N88T	17:7674223-7674223	18
15	COSM111775215	TP53	skin,face,carcinoma,squamous cell carcinoma	c.746G>C	p.R249T	17:7674217-7674217	18
16	COSM144129318	TP53	skin,face,carcinoma,squamous cell carcinoma	c.229T>C	p.Y77H	17:7674257-7674257	18
17	COSM144088618	TP53	skin,face,carcinoma,squamous cell carcinoma	c.160C>T	p.R54*	17:7674894-7674894	18
18	COSM87910628	TP53	skin,face,carcinoma,squamous cell carcinoma	c.772G>A	p.E258K	17:7674191-7674191	18
19	COSM144662686	TP53	skin,face,carcinoma,squamous cell carcinoma	c.715C>T	p.P239S	17:7673788-7673788	18
20	COSM144650676	TP53	skin,face,carcinoma,squamous cell carcinoma	c.457C>T	p.Q153*	17:7674957-7674957	18
21	COSM142560553	TP53	skin,face,carcinoma,squamous cell carcinoma	c.625C>T	p.R209W	17:7674221-7674221	18
22	COSM93194159	TP53	skin,face,carcinoma,squamous cell carcinoma	c.832C>T	p.P278S	17:7673788-7673788	18
23	COSM142560281	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.626G>A	p.R209Q	17:7674220-7674220	18
24	COSM93183975	TP53	skin,face,carcinoma,squamous cell carcinoma	c.742C>T	p.R248W	17:7674221-7674221	18
25	COSM93199912	TP53	skin,face,carcinoma,squamous cell carcinoma	c.746G>C	p.R249T	17:7674217-7674217	18
26	COSM144023384	TP53	skin,face,carcinoma,squamous cell carcinoma	c.739G>A	p.E247K	17:7674191-7674191	18
27	COSM145020185	TP53	skin,face,carcinoma,squamous cell carcinoma	c.520C>T	p.R174*	17:7674894-7674894	18
28	COSM105630961	TP53	skin,face,carcinoma,squamous cell carcinoma	c.782+393C>T	p.?	17:7673788-7673788	18
29	COSM111758130	TP53	skin,face,carcinoma,squamous cell carcinoma	c.574C>T	p.Q192*	17:7674957-7674957	18
30	COSM122749884	TP53	skin,face,carcinoma,squamous cell carcinoma	c.350G>C	p.R117T	17:7674217-7674217	18
31	COSM106052835	TP53	skin,face,carcinoma,squamous cell carcinoma	c.574C>T	p.Q192*	17:7674957-7674957	18
32	COSM144023287	TP53	skin,face,carcinoma,squamous cell carcinoma	c.799C>T	p.P267S	17:7673788-7673788	18
33	COSM142838067	TP53	skin,face,carcinoma,squamous cell carcinoma	c.586C>T	p.R196*	17:7674945-7674945	18
34	COSM143946062	TP53	skin,face,carcinoma,squamous cell carcinoma	c.160C>T	p.R54*	17:7674894-7674894	18
35	COSM121887849	TP53	skin,face,carcinoma,squamous cell carcinoma	c.436C>T	p.P146S	17:7673788-7673788	18
36	COSM144652672	TP53	skin,face,carcinoma,squamous cell carcinoma	c.739G>A	p.E247K	17:7673764-7673764	18
37	COSM142843719	TP53	skin,face,carcinoma,squamous cell carcinoma	c.454C>T	p.P152S	17:7675158-7675158	18
38	COSM87910495	TP53	skin,face,carcinoma,squamous cell carcinoma	c.832C>T	p.P278S	17:7673788-7673788	18
39	COSM105619751	TP53	skin,face,carcinoma,squamous cell carcinoma	c.574C>T	p.Q192*	17:7674957-7674957	18
40	COSM144318661	TP53	skin,face,carcinoma,squamous cell carcinoma	c.655G>A	p.E219K	17:7674191-7674191	18
41	COSM144091278	TP53	skin,face,carcinoma,squamous cell carcinoma	c.263A>C	p.N88T	17:7674223-7674223	18
42	COSM144652296	TP53	skin,face,carcinoma,squamous cell carcinoma	c.469C>T	p.R157*	17:7674945-7674945	18
43	COSM144311933	TP53	skin,face,carcinoma,squamous cell carcinoma	c.520C>T	p.R174*	17:7674894-7674894	18
44	COSM111812818	TP53	skin,face,carcinoma,squamous cell carcinoma	c.706T>C	p.Y236H	17:7674257-7674257	18
45	COSM105627464	TP53	skin,face,carcinoma,squamous cell carcinoma	c.260C>A	p.P87Q	17:7676109-7676109	18
46	COSM144013676	TP53	skin,face,carcinoma,squamous cell carcinoma	c.709C>T	p.R237W	17:7674221-7674221	18
47	COSM122734399	TP53	skin,face,carcinoma,squamous cell carcinoma	c.346C>T	p.R116W	17:7674221-7674221	18
48	COSM142837995	TP53	skin,face,carcinoma,squamous cell carcinoma	c.375+1G>A	p.?	17:7675993-7675993	18
49	COSM106055208	TP53	skin,face,carcinoma,squamous cell carcinoma	c.637C>T	p.R213*	17:7674894-7674894	18
50	COSM142881780	TP53	skin,face,carcinoma,squamous cell carcinoma	c.706T>C	p.Y236H	17:7674257-7674257	18

Copy number variations for Squamous Cell Carcinoma from CNVD:

⁶ (show top 50) (show all 98)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	13821	1	1	7200000	Copy number	TP73	Squamous cell cancer
2	25151	1	184907591	184916179	Amplification	PTGS2	Squamous cell cancer
3	31938	1	32200000	39600000	Copy number		Squamous cell cancer
4	33706	1	47467454	47552406	Amplification	STIL	Squamous cell cancer
5	42802	10	40300000	135374737	Copy number		Squamous cell cancer
6	49690	11	110000000	134452384	Copy number		Squamous cell cancer
7	49993	11	112500000	114500000	Copy number	CADM1	Squamous cell cancer
8	57469	11	63400000	77100000	Copy number	GSTP1	Squamous cell cancer
9	57471	11	63400000	77100000	Copy number	MEN1	Squamous cell cancer
10	61508	12	1	3100000	Gain		Squamous cell cancer
11	61509	12	1	3100000	Gain	SLC6A12	Squamous cell cancer
12	61511	12	1	3100000	Gain	SLC6A13	Squamous cell cancer
13	61529	12	1	35400000	Copy number		Squamous cell cancer
14	61608	12	10000000	12600000	Gain	CDKN1B	Squamous cell cancer
15	61609	12	10000000	12600000	Gain	APOLD1	Squamous cell cancer
16	66096	12	25249446	25295130	Amplification	KRAS	Squamous cell cancer
17	66577	12	3100000	5300000	Gain		Squamous cell cancer
18	66579	12	3100000	5300000	Gain		Squamous cell cancer
19	66581	12	3100000	5300000	Gain	TSPAN9	Squamous cell cancer
20	75264	13	18400000	72100000	Copy number		Squamous cell cancer
21	77032	13	39500000	46200000	Copy number		Squamous cell cancer
22	87575	14	74815283	74818665	Amplification	FOS	Squamous cell cancer
23	93656	15	57100000	61500000	Loss	RORA	Squamous cell cancer
24	95697	15	79500000	83000000	Loss	DNM1P41	Squamous cell cancer
25	95699	15	79500000	83000000	Loss		Squamous cell cancer
26	95701	15	79500000	83000000	Loss		Squamous cell cancer
27	95703	15	79500000	83000000	Loss		Squamous cell cancer
28	95705	15	79500000	83000000	Loss		Squamous cell cancer
29	95707	15	79500000	83000000	Loss	LOC440300	Squamous cell cancer
30	95709	15	79500000	83000000	Loss		Squamous cell cancer
31	97922	16	14700000	16700000	Loss		Squamous cell cancer
32	107539	17	15900000	22100000	Loss		Squamous cell cancer
33	111141	17	35097918	35138441	Amplification	ERBB2	Squamous cell cancer
34	116535	17	6800000	11200000	Copy number		Squamous cell cancer
35	122734	18	59800000	76117153	Copy number		Squamous cell cancer
36	123838	18	89115825	89123587	Amplification	SPP1	Squamous cell cancer
37	124166	19	1	6900000	Gain	BSG	Squamous cell cancer
38	124167	19	1	6900000	Gain	ODF3L2	Squamous cell cancer
39	124168	19	1	6900000	Gain	TPGS1	Squamous cell cancer
40	124170	19	1	6900000	Gain	CDC34	Squamous cell cancer
41	124171	19	1	6900000	Gain	GZMM	Squamous cell cancer
42	124173	19	1	6900000	Gain	MADCAM1	Squamous cell cancer
43	124175	19	1	6900000	Gain		Squamous cell cancer
44	135627	2	118600000	122100000	Gain		Squamous cell cancer
45	166091	3	1	3500000	Loss	APOD	Squamous cell cancer
46	166092	3	1	3500000	Loss	CCR2	Squamous cell cancer
47	166093	3	1	3500000	Loss	CCRL2	Squamous cell cancer
48	169828	3	14700000	30800000	Copy number		Squamous cell cancer
49	171547	3	169200000	172500000	Gain	MECOM	Squamous cell cancer
50	171549	3	169200000	172500000	Gain		Squamous cell cancer